Objectives Severe fever with thrombocytopenia syndrome (SFTS) has no vaccine or treatment and an extremely high fatality rate. We aimed to analyze and evaluate the risk factors for death associated with SFTS.
Methods Among reports from 2018 to 2022, we compared and analyzed 1,034 inpatients aged 18 years or older with laboratory-confirmed SFTS who underwent complete epidemiological investigations.
Results Most of the inpatients with SFTS were aged 50 years or older (average age, 67.6 years). The median time from symptom onset to death was 9 days, and the average case fatality rate was 18.5%. Risk factors for death included age of 70 years or older (odds ratio [OR], 4.82); agriculture-related occupation (OR, 2.01); underlying disease (OR, 7.20); delayed diagnosis (OR, 1.28 per day); decreased level of consciousness (OR, 5.53); fever/chills (OR, 20.52); prolonged activated partial thromboplastin time (OR, 4.19); and elevated levels of aspartate aminotransferase (OR, 2.91), blood urea nitrogen (OR, 2.62), and creatine (OR, 3.21).
Conclusion The risk factors for death in patients with SFTS were old age; agriculture-related occupation; underlying disease; delayed clinical suspicion; fever/chills; decreased level of consciousness; and elevated activated partial thromboplastin time, aspartate aminotransferase, blood urea nitrogen, and creatine levels.
Citations
Citations to this article as recorded by
Seroprevalence and Epidemiological Characteristics of Severe Fever with Thrombocytopenia Syndrome in Patients with Chronic Diseases in Korea Jongyoun Yi, Ahreum Kim, Maeng Seok Noh, Changhoon Kim, Hyun Jin Son, Mee Kyung Ko, Kye-Hyung Kim Viruses.2026; 18(2): 217. CrossRef
Overwintering Ticks as a Reservoir for Severe Fever With Thrombocytopenia Syndrome Virus in the Republic of Korea Hyunyoung Yoon, Hee Il Lee, Seong Yoon Kim Entomological Research.2026;[Epub] CrossRef
Identification of early prognostic biomarkers in Severe Fever with Thrombocytopenia Syndrome using machine learning algorithms Jie Zhu, Jianmei Zhou, Chunhui Tao, Guomei Xia, Bingyan Liu, Xiaowei Zheng, Xu Li, Zhenhua Zhang Annals of Medicine.2025;[Epub] CrossRef
The immunogenicity and protection efficacy evaluation of mRNA vaccine candidate for severe fever with thrombocytopenia syndrome in mice Da-Eun Jeong, Jack Yoon, Baek Kim, Jun-Gu Kang, Abdallah M. Samy PLOS Neglected Tropical Diseases.2025; 19(4): e0012999. CrossRef
Retrospective Analysis of Severe Fever With Thrombocytopenia Syndrome and Construction of a Nomogram Prediction Model for Mortality Risk Factors Gang Chen, Yuchen Du, Xiuchang Ma, Yaowen Liang, Apeng Chen, Jie Wei, Jinhuan Wu, Wenxian Qian, Shuqin Xie, Yi Yan, Zheng Hu, Yishan Zheng, Man Tian, Changhua Yi Open Forum Infectious Diseases.2025;[Epub] CrossRef
Deciphering the evolutionary landscape of severe fever with thrombocytopenia syndrome virus across East Asia Dongbin Park, Kwan Woo Kim, Young-Il Kim, Mark Anthony B Casel, Hyunwoo Jang, Woohyun Kwon, Kanghee Kim, Se-Mi Kim, Monford Paul Abishek N, Eun-Ha Kim, Hobin Jang, Suhee Hwang, Seok-Min Yun, Joo-Yeon Lee, Hye Won Jeong, Su-Jin Park, Young Ki Choi Virus Evolution.2024;[Epub] CrossRef
Acute kidney injury as a prognostic marker in severe fever with thrombocytopenia syndrome Jin Mi Lee, Hae Lee Kim, Myoung-nam Lim, Changhyup Kim, Yeon Ju La, Yong Duk Jeon, Won Sup Oh, Seongmin Son, Sunhwa Lee, Hyunjeong Baek, Daniel Duck-Jin Hwang, Ji In Park Scientific Reports.2024;[Epub] CrossRef
Double-Stranded RNA-Based Method for Diagnosing Severe Fever with Thrombocytopenia Jung Wan Park, Jaemin Jeon, Yoosik Kim, Min Hyok Jeon Journal of Clinical Medicine.2024; 14(1): 105. CrossRef
Objectives We estimated the overall and age-specific percentages of the Korean population
with presumed immunity against severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) as of April 2022 using the national registry.
Methods We used the national coronavirus disease 2019 (COVID-19) infection and vaccination
registry from South Korea, as described to define individuals with a previous history of
COVID-19 infection, vaccination, or both, as persons with presumed immunity.
Results Of a total of 53,304,627 observed persons, 24.4% had vaccination and infection, 58.1%
had vaccination and no infection, 7.6% had infection and no vaccination, and 9.9% had no
immunity. The SARS-CoV-2 Omicron variant emerged at a time when the presumed population
immunity ranged from 80% to 85%; however, nearly half of the children were presumed to
have no immunity.
Conclusion We report a gap in population immunity, with lower presumed protection in
children than in adults. The approach presented in this work can provide valuable informed
tools to assist vaccine policy-making at a national level.
Citations
Citations to this article as recorded by
Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022 In Hwa Jeong, Jong-Hun Kim, Min-Jung Kwon, Jayoung Kim, Hee Jin Huh, Byoungguk Kim, Junewoo Lee, Jeong-hyun Nam, Eun-Suk Kang Journal of Korean Medical Science.2024;[Epub] CrossRef
Epidemiology of Coronavirus Disease 2019 in Infants and Toddlers, Seoul, South Korea JiWoo Sim, Euncheol Son, Young June Choe Pediatric Infection & Vaccine.2024; 31(1): 94. CrossRef
Predicting adherence to COVID-19 preventive measures among South Korean adults aged 40 to 69 Years using the expanded health empowerment model Su-Jung Nam, Tae-Young Pak SSM - Population Health.2023; 22: 101411. CrossRef
Acute COVID-19 in unvaccinated children without a history of previous infection during the delta and omicron periods Jee Min Kim, Ji Yoon Han, Seung Beom Han Postgraduate Medicine.2023; 135(7): 727. CrossRef
First
Prev
